Data as of Oct 17
| +7.81 / +3.61%|
The 14 analysts offering 12-month price forecasts for Intercept Pharmaceuticals Inc have a median target of 499.50, with a high estimate of 693.00 and a low estimate of 172.00. The median estimate represents a +122.54% increase from the last price of 224.45.
The current consensus among 14 polled investment analysts is to Buy stock in Intercept Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.